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Abstract
Biallelic Parkin (PRKN) mutations cause autosomal recessive Parkinson’s disease (PD); however, the role of monoallelic PRKN
mutations as a risk factor for PD remains unclear. We investigated the role of single heterozygous PRKN mutations in three
large independent case-control cohorts totalling 10 858 PD cases and 8328 controls. Overall, after exclusion of biallelic
carriers, single PRKN mutations were more common in PD than controls conferring a >1.5-fold increase in the risk of PD
[P-value (P) = 0.035], with meta-analysis (19 574 PD cases and 468 488 controls) confirming increased risk [Odds ratio
(OR) = 1.65, P = 3.69E-07]. Carriers were shown to have significantly younger ages at the onset compared with non-carriers
(NeuroX: 56.4 vs. 61.4 years; exome: 38.5 vs. 43.1 years). Stratifying by mutation type, we provide preliminary evidence for a
more pathogenic risk profile for single PRKN copy number variant (CNV) carriers compared with single nucleotide variant
carriers. Studies that did not assess biallelic PRKN mutations or consist of predominantly early-onset cases may be biasing
these estimates, and removal of these resulted in a loss of association (OR = 1.23, P = 0.614; n = 4). Importantly, when we
looked for additional CNVs in 30% of PD cases with apparent monoallellic PRKN mutations, we found that 44% had biallelic
mutations, suggesting that previous estimates may be influenced by cryptic biallelic mutation status. While this study
supports the association of single PRKN mutations with PD, it highlights confounding effects; therefore, caution is needed
when interpreting current risk estimates. Together, we demonstrate that comprehensive assessment of biallelic mutation
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Introduction
Parkinson’s disease (PD) is a multifactorial neurodegenerative
disease. Common variations within 78 independent loci increase
PD risk (1). Pathogenic mutations in autosomal dominant genes
[leucine-rich repeat kinase 2 (LRRK2), α-synuclein (SNCA) and
vacuolar protein sorting 35, yeast, homolog of (VPS35)] as
well as biallelic mutations in autosomal recessive (AR) genes
[PRKN, Parkinsonism associated deglycase (PARK7) or DJ-1, PTEN-
induced putative kinase 1 (PINK1) and F-box protein 7 (FBXO7)]
cause Mendelian PD (2). It has been suggested that single
heterozygous pathogenic AR mutations can increase the risk
of PD, and several lines of evidence have been provided for and
against mutations (reviewed in Klein et al.) (3). Previous studies
may have been confounded by the differences in methods for
mutation detection in cases and controls. Biallelic AR mutations
in PD genes are rare in PD cases, but single heterozygous
mutations in specific AR PD genes are more common and are
estimated, depending on the population, to occur in between
0.6 and 3% of unaffected control individuals (4–7). Accurate
estimation of any risk associated with single heterozygous
AR mutations is therefore essential for the counseling of
biallelic carriers, monoallelic carriers and their family members.
Furthermore, understanding the risk associated with single
AR mutations may provide important insights into disease
biology. Here, we investigate whether single carriers of disease-
causing PRKN mutations are at an increased risk for PD
using three large independent case-control cohorts using
exome-focused genotype data, whole exome sequencing and
resequencing (Reseq) data from the International Parkinson’s
Disease Genomics Consortium (IPDGC).
Results
We identified a total of 109 monoallelic PRKN mutation carriers
in 12 251 PD cases and controls (72 PD, 37 controls), carrying 19
different PRKN variants known to cause AR PD in the biallelic
state, using the NeuroX genotyping platform (8). It is possi-
ble that the identified PD cases represent misclassified true
biallelic PRKN PD cases. To confirm whether PD cases carry
a single pathogenic allele or whether a second variant was
missed, we (i) reviewed diagnostic reports if available (n = 4) or (ii)
assessed available samples using multiplex ligation-dependent
probe amplification (MLPA, n = 29). Of the 33 available NeuroX
samples, representing ∼30% of our putative monoallelic indi-
viduals [five controls, 13.5%; 28 PD cases harbouring a sin-
gle heterozygous PKRN mutation (PD-monoallelic), 38.9%], six
cases (18% of the available samples, 21% of available PD cases)
were found to harbour a second mutation and therefore were
removed, leaving a total of 66 PD cases for all subsequent analy-
ses (no controls were found to harbour a second mutation).
After removal of cases with established Mendelian muta-
tions across all known PD genes, 1.0% (66/6552) of PD cases
were found to harbour single heterozygous PRKN PD-causing
mutations [either heterozygous copy number variants (CNVs)
or single nucleotide variants (SNVs), Table 1], compared with
0.6% (37/5693) of controls. Single heterozygote mutations might
increase the PD risk [Odds ratio (OR) = 1.55; 95% confidence inter-
val (CI):1.03, 2.33; P-value (P) = 0.035], although ∼70% of putative
monogenic cases were not assessed for a second mutation.
Although speculative, if the remaining apparent monoallelic
cases had a similar rate of occult biallelic mutations, then the
true underlying monoallelic carrier rate could be estimated to be
lower at 0.9%, and there would be no difference between cases
and controls (OR = 1.39; 95% CI: 0.90, 2.16; P = 0.117). Using age at
onset (AAO) data from 5710 (87.1%) cases, we found that NeuroX
PD cases with single PRKN mutations have significantly lower
AAOs (average = 56.4 years) than cases without known mutations
[average = 61.4 years; β-coefficient (Coeff) = −5.04; 95% CI: −8.32,
−1.71; P = 0.003].
We next sought to explore the potential increased risk in two
independent IPDGC case-control cohorts using exome sequenc-
ing (cases = 1235; controls = 473) (8) and Reseq data (cases = 3071;
controls = 2162). We identified 28 (23 cases, five controls) and 52
(36 cases, 16 controls) carriers of single PRKN mutations in the
exome [as previously described (8)] and Reseq data, respectively.
CNVs were not determined in the primary exome or Reseq
dataset. In the exome cohort, 1.9% (23/1231) of cases and 1.1%
(5/473) of controls, and in the Reseq cohort, 1.2% (36/3071) of
cases and 0.7% (16/2162) of controls harboured single PRKN SNVs.
Before searching for occult second mutations, a meta-analysis of
the three IPDGC (NeuroX, exome sequencing and Reseq) cohorts
revealed a significant ∼1.5-fold increased risk [OR = 1.57; 95%
CI: 1.15, 2.16; P = 0.005; proportion of total variation caused by
heterogeneity (I2) = 0.0%, Cochran’s Q-statistic test for hetero-
geneity P-value (Phet) = 0.960] associated with PRKN mutations
(Fig. 1). AAO data was available on 1130 PD exome cases (91.8%)
and 2599 Reseq cases (84.6%). Albeit non-significant, exome PD
cases carrying single PRKN SNVs had lower AAO compared with
non-carriers (average = 38.5 years vs. 43.1 years; Coeff = −4.34;
Table 1. NeuroX Parkinson’s risk profiles associated with single heterozygous PRKN mutations
Type N (Freq) OR (95% CI) Plog AAO (with
data)
Coeff (95% CI) Preg
Controls PD
All
With 37 (0.6%) 66 (1.0%) 1.55 (1.03, 2.32) 0.035 56.4 (86.4%) −5.04 (−8.34, −1.75) 0.003
Without 5656 6486 61.4 (87.2%)
CNV
With 4 (0.1%) 11 (0.2%) 2.53 (0.80, 7.99) 0.113 58.4 (90.0%) −3.11 (−11.15, 4.93) 0.449
Without 5689 6541 61.4 (87.2%)
SNV
With 33 (0.6%) 55 (0.8%) 1.43 (0.92, 2.21) 0.108 56.0 (85.5%) −5.41 (−9.02, −1.81) 0.003
Without 5660 6497 61.4 (87.2%)
Coeff, linear regression coefficient correcting for gender and principal components 1–4; Freq, frequency; N, number of samples; OR, odds ratio correcting for gender
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Figure 1. Forest plot of OR of the Parkinson’s risk associated with heterozygous PRKN mutations in three independent IPDGC cohorts.
95% CI: −8.95, 0.28; P = 0.066), with carriers having significantly
lower AAO in Reseq cases (average = 52.6 years vs. 60.5 years;
Coeff = −7.84; 95% CI: −12.59, −3.09; P = 0.001). We then used
MLPA to search for potentially missed PRKN CNVs in muta-
tion carriers. Four of the nine available exome deoxyribonu-
cleic acid (DNA) samples (44%, all PD cases) were found to
harbour a missed second mutation and were removed from the
subsequent analyses. Assuming a similar rate of occult bial-
lelic carriage across both datasets, the true rate of monoallelic
cases could be estimated to be 1.2 and 0.7% in the exome and
Reseq cases as compared with the 1.1 and 0.7% of the controls,
respectively.
We next performed a meta-analysis of available cohorts
and studies that reported heterozygous PD-causing mutation
rates in cases and controls, from European ancestry cohorts
only. Three cohorts (Parkinson’s Progression Markers Initiative,
PPMI, https://www.ppmi-info.org/; UK Biobank Genotyping and
Exome cohorts, https://www.ukbiobank.ac.uk/) and 21 published
studies were included in our analyses (5,6,9–27). Including
our cohorts, the meta-analysis revealed a significant 1.65-fold
increased PD risk in single PRKN mutation carriers (95% CI: 1.36,
2.00; P = 3.69E-07; I2 = 0.0%, Phet = 0.594) (Fig. 2).
As in our study, occult second mutations are likely biasing
these estimates, so we therefore restricted our meta-analysis
to nine studies (9/21, 43%) that searched for a second PRKN
mutation (Table 2). Based on these studies, single PRKN muta-
tions confer a 2-fold increase in PD risk in carriers (OR = 2.00,
95% CI: 1.10, 3.62, P = 0.023; I2 = 1.3%, Phet = 0.423) (Supplementary
Material, Fig. S1).
Inclusion of studies that used predominantly early-onset
PD (EOPD) cases may additionally be inflating these estimates;
we therefore repeated the meta-analysis excluding these EOPD
studies (15/21, 71%), which demonstrated a 1.5-fold significant
increased risk in carriers (OR = 1.50, 95% CI: 1.22, 1.84; P = 1.05E-
04; I2 = 0%, Phet = 0.927) (Supplementary Material, Fig. S2).
Restricting our analysis to the four non-EOPD studies, that
searched for biallelic carriers, demonstrated that single PRKN
mutations were not associated with an increased PD risk in
these cohorts (OR = 1.23, 95% CI: 0.55, 2.75, P = 0.614; I2 = 0.0%,
Phet = 0.657; Supplementary Material, Fig. S3).
The pathogenicity of the common PRKN p.R275W variant
in AR PD is not as clear cut as other PRKN mutations. To test
whether the observed SNV association is driven by p.R275W,
we repeated the meta-analysis after excluding this variant.
Removal of p.R275W resulted in a marginally increased estimate
(OR = 1.76, 95% CI: 1.37, 2.28, P = 1.42E-05; I2 = 0.0%, Phet = 0.673;
Supplementary Material, Table S1; Fig. S4). Limiting our analysis
to the eight cohorts which assessed biallelic mutations indicated
a >2-fold increased risk (OR = 2.41, 95% CI: 1.17, 4.96, P = 0.017;
I2 = 0.0%, Phet = 0.791) (Supplementary Material, Fig. S5).
The contribution of biallelic PRKN CNVs to AR PD is well
established; however, that of heterozygous CNV carriers remains
unclear. We identified monoallelic PRKN CNVs in 0.17% (11/6552)
of non-Mendelian PD cases compared with 0.07% (4/5693) con-
trols (Table 1) using the NeuroX data only. None of these CNV
carriers overlapped with NeuroX SNV carriers. There was a >2.5-
fold increase in PD risk for PRKN CNV heterozygote carriers
compared with controls (OR = 2.53; 95% CI: 0.80, 7.99; P = 0.113),
but this was not statistically significant.
It has been suggested that monoallelic PRKN CNVs might
confer a higher risk that is associated with a more pathogenic
profile compared with other AR mutations (28). To assess this, we
compared differences in risk between CNV and SNVs carriers in
the NeuroX cohort. A total of 55 PRKN SNV carriers were seen
in non-Mendelian PD cases (55/6552; 0.8%) compared with 33
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Figure 2. Forest plot of the OR of the Parkinson’s risk associated with heterozygous PRKN mutations.
Table 2. Meta-analyses of heterozygous PRKN mutation carriers in studies that investigated and excluded PD patients with biallelic PRKN
mutations
Study PD Controls OR (95% CI)
Carrier Non-carrier Carrier Non-carrier
Benitez et al. 2016 3 466 2 335 1.08 (0.18–6.49)
Brooks et al. 2009 9 241 5 271 2.02 (0.67–6.12)
Clark et al. 2006 5 95 0 105 12.15 (0.66–222.68)
Hertz et al. 2006 5 82 0 50 6.73 (0.37–124.37)
Klein et al. 2005 1 62 0 100 4.82 (0.19–120.27)
Lesage et al. 2008 9 150 0 170 21.35 (1.24–372.96)
Lincoln et al. 2003 9 304 6 186 0.92 (0.32–2.62)
Spataro et al. 2017 4 240 1 144 2.40 (0.27–21.68)
Wiley et al. 2004 5 96 0 45 5.19 (0.28–95.82)
Pooled 50 1736 9 1406 2.00 (1.10–3.62)
Carrier, number of samples harbouring mutation, PRKN, Parkin (NM_013988 and NM_004562).
(Table 1). To test whether PRKN CNVs confer a more ‘pathogenic’
risk profile compared with SNVs, we performed AAO analysis in
the NeuroX data only. Carriers of heterozygous PRKN CNVs had a
mean AAO of 58.4 years, compared with non-carriers (61.4 years)
(Coeff = −3.11; 95% CI: −11.15, 4.93; P = 0.449).
To further investigate the potential different risk profiles, we
performed separate meta-analyses of published PRKN mutation
data for SNVs and CNVs. Meta-analyses, including the current
data, revealed significant independent increased PD risks for
SNVs (OR = 1.56, 95% CI: 1.22, 2.00, P = 4.46E-04; I2 = 0%, Phet = 0.968)
and CNVs (OR = 1.85, 95% CI: 1.38, 2.50, P = 4.55E-05; I2 = 0.0%,
Phet = 0.640) (Fig. 3; Supplementary Material, Table S2). Restricting
our meta-analysis to studies that searched for second hits sug-
gested that PD risk was larger in the carriers of single PRKN
CNVs (OR = 3.11, 95% CI: 1.23, 7.89, P = 0.016; I2 = 0.0%, Phet = 0.879)
compared with those harbouring heterozygous SNVs (OR = 1.59,
95% CI: 0.79, 3.20, P = 0.191; I2 = 0.0%, Phet = 0.785).
Discussion
The role of rare biallelic mutations in PRKN in AR PD (MIM#600116)
is well established. Here, using data from a large PD case-
control cohort, we identified a total of 109 carriers of single
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Figure 3. Forest plot of the OR of the Parkinson’s risk associated with heterozygous PRKN SNV and CNV carriers.
with known mutations, we demonstrated that carriers of
single mutations were at a small but significantly increased
risk of PD (OR = 1.55; 95% CI: 1.03, 2.33; P = 0.035). This was
confirmed by a meta-analysis with two additional IPDGC
cohorts (cases = 10 954; controls = 8328) which demonstrated
a significant >1.5-fold increased risk (P = 0.005). Carriers also
had significantly lower AAOs than non-carriers (56.4 years
vs. 61.4 years; P = 0.003). Similar findings were seen in the
exome and Reseq data for increased risk [exome, OR = 2.20;
Reseq, OR = 1.59] and younger AAOs compared with non-carriers
(exome, 38.5 years vs. 43.1 years; Reseq, 52.6 years vs. 60.5 years).
A meta-analysis of 19 574 PD cases and 468 488 controls from 27
cohorts further confirmed that heterozygous PRKN mutations
confer an increased PD risk (OR = 1.65; P = 3.69E-07). However,
several confounding factors are likely biasing these estimates
in favour of increased risk and are explored in this study.
Large-scale studies in systematically recruited cohorts that
have comprehensively interrogated biallelic PRKN mutations are
therefore needed to accurately determine the risk associated
with single mutations.
The relatively common p.R275W (c.823C > T, rs34424986)
variant, the most frequent PD-associated variant in PRKN, has
not been reported in the homozygous state and has only been
reported in compound heterozygotes with another mutation
in multiple AR PD families (MIM#602544), and it has been
classified as likely pathogenic. p.R275W reduces protein stability
by disrupting binding to phosphorylated ubiquitin and results in
reduced Parkin (PRKN) levels (29), supporting the pathogenicity
of p.R275W. We examined whether the increased PD risk
associated with single PRKN variants was driven by this variant.
The observation that the OR increases after removal suggests
that p.R275W may have reduced effect on enzyme activity
compared with other mutations, and that, because of its more
common frequency, its presence may be diluting the true effect
of heterozygous PRKN mutations in PD biology.
Our analysis provides some support for a more ‘pathogenic’
risk profile associated with PRKN CNVs as compared with
SNVs (CNVs, OR = 2.53; SNVs, OR = 1.43) in the NeuroX data.
Both mutation types appear to be associated with lower AAOs;
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definitive conclusions from being drawn. While the meta-
analysis results here support the increased risk for PRKN CNV
carriers (OR = 1.85), albeit marginally higher than PRKN SNVs
(OR = 1.56), the increased risk associated with PRKN CNVs
should be interpreted with care. Small sample sizes, low CNV
frequency and failure to investigate/report CNVs may have
resulted in an underestimated effect size seen in the meta-
analysis. Failure to conclusively look for second PRKN hits
may also be a potential confounder when trying to estimate
the risk associated with single PRKN mutations. Additional
work in larger cohorts where both PRKN SNVs and CNVs are
routinely assessed is therefore needed to gain more accurate
insight into the different risk profiles associated with different
mutation types.
This large study builds on previous work looking at single
PRKN mutations in PD aetiology. While several studies failed to
identify single known pathogenic PRKN mutations in controls
thereby supporting increased disease risk, others have found
equal frequencies in both cases and controls providing evidence
against increased risk (4,7,13,17,18,30–32). These estimates
have, however, been based on relatively small sample sets
which have made it difficult to conclusively determine if single
mutations confer any risk. The inclusion of non-ClinVar (https://
www.ncbi.nlm.nih.gov/clinvar/) variants represents a potential
confounder in that we may be overestimating the frequency of
disease relevant single PRKN mutations. Limiting our analyses
to ClinVar variants only did not result in considerably different
risk estimates across all comparisons (all studies, OR = 1.70,
P = 2.65E-07; biallelic studies, OR = 1.99, P = 0.036; non-EOPD
studies, OR = 1.55, P = 5.6E-05). Another confounder relates to
the fact that we observed a significant rate of occult second
pathogenic mutations in putative monoallelic cases in our
NeuroX cohort. The detected rate of occult biallelic carrier
status was high in our two datasets (6/28, 21% and 4/9, 44%),
approaching one-half of PD cases with apparent monoallelic
status. Additionally, several studies included in the analyses
here have not searched for potentially hidden biallelic mutations
in all cases and controls or have only interrogated a subset of
PRKN mutations. Inclusion of these PD cases in our analysis is
likely to appreciably influence our estimate. However, restricting
the meta-analyses to nine cohorts that searched for biallelic
PRKN mutations in all cases and controls, demonstrated that
single mutations confer a 2-fold increase in risk in carriers. A
further confounding factor is the use of EOPD cases (<50 years) in
such studies which may be additionally inflating risk estimates
as PRKN mutations are more likely to occur in PD cases of
younger onset. This was observed in the IPDGC cohorts, with a
higher estimate in the exome cohort compared with the NeuroX
and Reseq cohorts. The additional removal of predominantly
EOPD studies resulted in the loss of the original association
(OR = 1.23; P = 0.614), but this was based on a few small studies
(n = 4). This suggests that the current estimates of the effect of
single mutations in modulating PD risk may not be accurate
but also stresses the importance of comprehensively searching
for biallelic mutations in systematically recruited cohorts.
It remains possible that there are further ‘occult’ coding
variants of unknown significance or non-coding mutations
affecting the promoter or splicing regions that have not yet
been identified.
There are some limitations to our study. NeuroX biallelic and
monoallelic cases will have been missed as not all possible PD-
causing variants are represented on the chip, with only 16.8%
of known pathogenic variants present (33) (Supplementary
Material, Table S3). The same applies to the detection of biallelic
carriers in the UK Biobank genotyping cohort. Identifying
PRKN CNVs from the NeuroX variant genotype data using
PennCNV may have missed smaller deletions/duplications.
The false-positive rate of PennCNV as a method for CNV
detection was estimated to be 9.0–17.7%, with false-positive
CNVs predominantly small in size and occurring regardless of
genotyping chip used (34). Our CNV detection of false positive
rate in the NeuroX cohort is 6.9%. However, the fact that (i) the
NeuroX variants are not evenly distributed across the PRKN locus
(accounts for four misclassified samples) and that (ii) we were
looking for CNVs as small as a single exon may have resulted
in our approach missing or inaccurately calling CNVs in our
large cohort comprising predominantly of late-onset PD cases.
There are limitations in defining CNVs from the IPDGC and
UK Biobank exome data, so CNVs were only investigated using
MLPA in identified PD-monoallelic exome cases. As the exome
cohort predominantly consists of EOPD cases, it is likely that
additional PRKN CNVs carriers were undetected. We therefore
sought to validate the monoallelic status of the available carriers
by accessing the diagnostic reports or by directly assessing
CNVs using MLPA and discovered a high rate of undetected
second hits in both our datasets. Previous studies which have
not systematically searched for second hits may have therefore
erroneously determined the monoallelic carrier rate, meaning
that the estimates derived from our in-house cohorts and other
published meta-analyses may not be accurate. It is therefore
very important that any proposed increased risk associated with
single PRKN mutations be considered with caution as, based on
findings presented here, a substantial part of the reported excess
on monoallelic carriers may relate to occult biallelic status.
Across AR diseases, there is a great deal of interest in the
potential role of single heterozygous mutations as risk factors
for disease. Heterozygous PINK1 mutations in PD (35) and MUTYH
mutations in colorectal cancer (36) do not confer an increased
risk of PD or cancer, respectively. However, single AR mutations
may increase the risk of related, but separate conditions from the
prototypic recessive disease. Single CFTR mutation carriers are
more susceptible to cystic fibrosis-related conditions (37), and
monoallelic ATM mutation carriers have higher risks for cancers
and ischemic heart disease—especially breast cancer in female
carriers. This current study highlights the importance of ensur-
ing that all potential confounders are taken into consideration
when assessing single mutations as any unaccounted-for biases
would generate inaccurate risk estimates and have significant
repercussions on the counseling of patients and their family
members.
In conclusion, while much of the data demonstrate that
harbouring a single heterozygous PRKN mutation increases PD
risk and that single PRKN CNVs may be more pathogenic than
PRKN SNVs, there may be confounding factors. This is supported
by our finding of no increased risk associated with single PRKN
mutations upon restricting our analysis to studies that assessed
biallelic mutations in cases and controls and studies that did
not include predominantly EOPD cases. Before the risk asso-
ciated with single heterozygous mutations can be accurately
defined, we highlight the importance of assessing ‘second hits’
in all cases and controls, where both SNVs and CNVs are sys-
tematically interrogated in large-scale cohorts that have been
systematically recruited.
Materials and Methods
High-quality genotype data from the NeuroX chip on 6558
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IPDGC [Database of Genotypes and Phenotypes (dbGaP) Study
Accession number: phs000918.v1.p1] (see Supplementary
Material, Table S4 for full list of PRKN variants captured).
Sample collection and variant genotyping have been described
elsewhere (33). IPDGC exome sequencing data from 1235 PD
cases and 473 controls were used as a replication cohort [Euro-
pean Genome-phenome Archive (EGA) Study Accession num-
bers: EGAS00001002103, EGAS00001002110, EGAS00001002113,
EGAS00001002156; dbGaP Study Accession number: phs001103.
v1.p1] and are described elsewhere (8). Additional replica-
tion cohorts used include: IPDGC Reseq cohort (cases = 3071,
controls = 2162), UK Biobank Genotyping (cases = 1428, con-
trols = 312 098; downloaded April 2018, under application
number 33601) and UK Biobank exome sequencing (cases = 114,
controls = 38 263; downloaded May 2019) cohorts and the
PPMI Exome sequencing de novo cohort (cases = 385, con-
trols = 179). The IPDGC Reseq cohort (PD: 54.8% male, average
AAO = 63.8 years; controls: 44.8% male, average age at recruit-
ment = 60.4 years) targeted sequencing genetic data covering
PD-associated genes [including ATP13A2, FBXO7, GBA, LRRK2,
MAPT, PARK7 or DJ-1, PINK1, PLA2G6, PRKN, SNCA and VPS35]
(35,38). Duplicate samples were removed, where possible, from
all analyses. Samples with missing call rates >5% were excluded
during quality control. Variants (excluding synonymous) from
known Mendelian PD-causing genes were extracted. Pathogenic
mutations were identified as previously described (8). Rare
PRKN (NM_013988 and NM_004562) CNVs were identified in
the NeuroX cohort using PennCNV (34). CNVs spanning a
minimum of 10 variants were selected and visually confirmed.
Monoallelic PD cases were defined as those carrying a single
heterozygous pathogenic PRKN allele as defined according to
the Online Mendelian Inheritance in Man (OMIM) (http://o
mim.org/), the Movement Disorder Society Genetic mutation
database (https://www.mdsgene.org/) or the Parkinson Disease
Mutation Database (http://www.molgen.vib-ua.be/PDMutDB/)
(Supplementary Material, Table S4). Where available, samples
were investigated by (i) accessing sample diagnostic records or
by (ii) using MLPA [SALSA P051 v.D1 probe mix (Microbiology
Research Centre Holland, MRC-Holland, The Netherlands)] to
confirm their monoallelic status. Without phasing information,
any two PD-causing hits identified in an individual are assumed
to be in trans.
To assess whether the PD risk might be associated with
(i) all monoallelic variants, (ii) CNVs alone or (iii) SNVs alone,
as indicated by case-control differences, we used logistic regres-
sion correcting for gender and principal components 1–4 (C1–4).
Linear regression was used to investigate the impact of single AR
mutations on AAO.
A literature review was undertaken (on 1 October 2019)
to identify published data on heterozygous PRKN muta-
tions, using search terms including combinations of the
following terms: Parkinson’s disease, PD, PRKN, PARK2 and
heterozygous. Additional studies were identified by manual
search of references cited in published articles. Should any
of the studies include previously published data, the most
recent data were selected where possible. Meta-analysis was
conducted using standard methods modeling fixed effects,
using Cochran’s Q-statistic to test for heterogeneity (Phet) (39)
and the I2 statistic (40) to quantify the proportion of the
total variation caused by heterogeneity relating to possible
differences in sample recruitment and assessment between
studies. Meta-analyses were performed for CNVs and SNVs
separately to investigate potential different risk profiles for each
mutation type.
Supplementary Material
Supplementary Material is available at HMG online.
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